Enter your email to access this webinar
About the Webinar
Join us for an in-depth look at how AI is leading to improvement in multiple facets across a drug’s lifecycle, and how that is leading to profound gains in time and financial returns. We will analyze the value of these improvements line by line and adjust outcomes based on different variables, including risk.
We will also cover real examples in which development teams are poised to achieve tens or even hundreds of millions of dollars in cost savings and efficiency gains, by significantly improving timelines and probability of trial success, using QuantHealth’s advanced trial simulation platform.
Leveraging data on more than 350 million patients and 100,000 drug entities, QuantHealth’s AI platform simulated over 5,000 protocol variations within minutes, pinpointing the most promising designs and shortening study timelines. This webinar will reveal how optimized protocols heightened the odds of technical success.
This event, hosted by Adam Petrich, MD, Chief Medical Officer of QuantHealth, will explore how AI is already profoundly impacting medicine.
Agenda
● Analyzing AI’s Impact: Where AI offers optimizations over the drug’s lifecycle
● Achieving Efficiency Gains: Uncovering the steps to reduce study duration, lower participant requirements, and streamline staffing needs.
● Maximizing Return on Investment: Translating advanced analytics into tangible savings, improved success odds, and accelerated drug development.
Meet the Speakers
Adam has extensive experience in all stages of oncology drug development (ranging from pre-IND to NDA/BLA), across a range of platforms (small molecules, mAb/ADC, immuno-oncology), spanning both solid tumors and hematologic malignancies. He has worked for and with many of today’s most innovative pharmaceutical companies, including AbbVie, Daiichi-Sankyo, AstraZeneca, and Roche/Genentech, and has extensive cross-functional and leadership experience and leadership, including clinical and commercial development, regulatory and medical affairs, business development, and and BD/licensing. He is trained as a hematologist and medical oncologist, and prior to joining the pharmaceutical industry, specialized in developmental therapeutics as a faculty member at the Feinberg School of Medicine and the Lurie Cancer Center, both at Northwestern University in Chicago.